Sciele backs out of Victory Pharma deal

Citing an "unforeseen development" that occurred after the deal was signed, Shionogi & Co said its subsidiary Sciele Pharma would not go through will its planned buyout of Victory Pharma. In May, Sciele announced it would buy Victory for $150 million. According to a release, the decision to cancel the deal was mutual. Shionogi's release

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.